Results

1–10 of 178 results for Clinical Trial

Multicenter Randomized Sham-Controlled Double-Masked Phase 2b Clinical Trial of Multi-Characteristic Opsin in Patients With Advanced Retinitis Pigmentosa
Peter K. Kaiser, MD FASRS
Annual Meeting Talks
2022
Baseline Factors Associated With 1-Year Outcomes in Phase III Comparison of SB11 (Approved Ranibizumab Biosimilar) With Reference Ranibizumab in nAMD
Neil M. Bressler, MD
Annual Meeting Talks
2022
One Year Follow-Up in a Phase ½ Clinical Trial of a Gene Modifier Therapy (OCU400) for the Treatment of Retinitis Pigmentosa
Benjamin Bakall, MD, PhD
Updates from the Field
2024
BVA Analysis of Low- or High-Dose MCO-010 Optogenetics Therapy for Retinitis Pigmentosa: First Time 100-Week TOPLINE Results From a Phase 2b/3 Clinical trial (RESTORE)
Michael A. Singer, MD
Updates from the Field
2024
Ixoberogene Soroparvovec (Ixo-vec) IVT Gene Therapy for Neovascular AMD: First Time 26-Week Interim Analysis Results from the Phase 2 LUNA Study
Charles C Wykoff, MD, PhD, FASRS
Updates from the Field
2024
Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Factors Associated With Fluctuations in Central Subfield Thickness in Patients With Diabetic Macular Edema Using 2 Clinical Trial Databases
Matthew Starr, MD
Annual Meeting Talks
2022
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Higher Order OCT Feature Assessment of the Impact of Fluid Dynamics on Visual Acuity in Neovascular AMD in a Phase III Clinical Trial: The Importance of Outer Retinal Integrity
Justis P. Ehlers, MD, FASRS
Annual Meeting Talks
2022
Relationship Between Number of Intermediate-Large Drusen and Geographic Atrophy Lesion Growth Rate in the Sham Groups of the DERBY, OAKS, and FILLY Trials
Eleonora Lad, MD, PhD
Annual Meeting Talks
2022